Hikma Pharmaceuticals PLC HKMPF
23.59 USD 0.00 (+0.00%)
At closeNov 10, 2026, 4:00 PM EST
23.00 Day range 23.00
16.34 52-week range 23.59
- YTD
- +12.63%
- 1 year
- +15.10%
News
marketbeat.com Hikma Pharmaceuticals Raises Profit Floor as Branded Growth Offsets Injectables Slowdown Hikma Pharmaceuticals LON: HIK maintained its 2026 revenue growth outlook and narrowed its operating profit guidance as stronger performance in its Branded business helped offset a…
marketbeat.com Hikma Pharmaceuticals Spotlights R&D Shift, Nasal Epinephrine Filing Progress Hikma Pharmaceuticals LON: HIK outlined a more centralized research and development strategy at the first event in its R&D Spotlight series, highlighting investments in respiratory, nasal, semi-solid…
fool.com Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.
proactiveinvestors.co.uk Panmure Liberum raises Hikma target price to 1,900p Panmure Liberum has raised its target price for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) from 1,600p to 1,900p, saying the drugmaker's strong first-half results support further upside in its…
proactiveinvestors.co.uk Jefferies lifts Hikma target as CMO deal underpins growth story Jefferies has raised its price target on Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) to 2,025p from 1,870p, pointing to the expanding contract manufacturing business as the source of the upgrade.…
proactiveinvestors.co.uk Citi sees Hikma discount as unwarranted after upgrade to forecasts Citi has raised its estimates for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) following stronger-than-expected half-year results, arguing that the FTSE 100 drugmaker's valuation discount is no…
proactiveinvestors.co.uk Hikma boost as broker raises price target Deutsche Bank has raised its target price for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) to 2,050p from 1,950p, reiterating its 'buy' rating on the FTSE 100 drugmaker. Kane Slutzkin said Hikma…
proactiveinvestors.com Hikma jumps 10% as brokers point to profit beat and undemanding rating Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares rose 10% to 1,721p after first-half results came in ahead of expectations on profits, with both Peel...
proactiveinvestors.co.uk Hikma jumps 10% as brokers point to profit beat and undemanding rating Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares rose 10% to 1,721p after first-half results came in ahead of expectations on profits, with both Peel Hunt and Stifel keeping buy ratings. The…
proactiveinvestors.co.uk Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive…
proactiveinvestors.co.uk Hikma recovery story still has further to run after recent rally, says Panmure Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) has already rebounded 30% from its lows but Panmure Liberum believes the generic drugmaker still offers upside if it can rebuild investor confidence…
proactiveinvestors.co.uk Citi starts Hikma at 'buy' with strategy reset offering compelling entry point Citi has initiated coverage of Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) with a 'buy' rating and a £17 price target, arguing the generic drugmaker's current valuation offers a compelling entry…
proactiveinvestors.com London BTC's Black Star project hits 16g/t gold as Nevada portfolio grows to four London BTC Company Ltd (LSE:BTC, OTCQB:VINZF) chairman David Lenigas joined Proactive's Stephen Gunnion to discuss the Black Star gold project and the...
proactiveinvestors.com AtaiBeckley to be acquired by Lilly in deal valued at up to $3.8 billion AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8...
proactiveinvestors.com Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval Medicus Pharma (NASDAQ:MDCX) said it has received US FDA feedback and central Institutional Review Board approval for its optimized Phase 2 study of...
seekingalpha.com Hikma Pharmaceuticals PLC (HKMPY) Sales/ Trading Statement Call Transcript Hikma Pharmaceuticals PLC (HKMPY) Sales/ Trading Statement Call Transcript
reuters.com UK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran war Hikma Pharmaceuticals reiterated its 2026 guidance on Thursday, adding that, while it has faced some pressure on shipping, energy, and insurance costs due to the war in the Middle East, a…
seekingalpha.com Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Prepared Remarks Transcript Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Prepared Remarks Transcript
seekingalpha.com Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Transcript Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Transcript
proactiveinvestors.co.uk Hikma Pharma tumbles on softer guidance as buyback fails to soften pill Hikma Pharmaceuticals PLC shares fell almost 16% to 1,390p after the drugs group delivered results for 2025 in line with forecasts but disappointed with weaker than expected guidance for 2026.…